Financials data is unavailable for this security.
View more
Year on year Yabao Pharmaceutical Group Co Ltd grew revenues 7.05% from 2.72bn to 2.91bn while net income improved 90.71% from 104.66m to 199.59m.
| Gross margin | 55.14% |
|---|---|
| Net profit margin | 6.68% |
| Operating margin | 8.75% |
| Return on assets | 4.85% |
|---|---|
| Return on equity | 7.16% |
| Return on investment | 6.22% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Yabao Pharmaceutical Group Co Ltd fell by 76.56m. However, the company earned 497.55m from its operations for a Cash Flow Margin of 17.10%. In addition the company used 127.37m on investing activities and also paid 446.75m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.99 |
|---|---|
| Tangible book value per share | 3.54 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.16 |
|---|---|
| Quick ratio | 1.64 |
| Total debt/total equity | 0.0849 |
|---|---|
| Total debt/total capital | 0.0779 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 200.00% and 91.29%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is below the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 1.05% |
|---|---|
| Div growth rate (5 year) | -9.71% |
| Payout ratio (TTM) | 51.10% |
| EPS growth(5 years) | -5.63 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 28.98 |
More ▼
